VANCOUVER, British Columbia, Sept. 22, 2022 (GLOBE NEWSWIRE) — LOVE Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has launched its Love Pharma online shop, a fully integrated e-commerce platform featuring its proprietary products, BLOOM and Auralief. From the company’s new e-commerce platform (https://lovepharmashop.com), consumers can directly purchase the company’s products.
For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on “InvestmentPitch” and on “YouTube”. If these links are not enabled, please visit www.InvestmentPitch.com and enter “Love Pharma” in the search box.
The technology infrastructure and applications are designed to leverage social and digital media campaigns independently, thereby driving specific consumers directly to individual online landing pages where they can seamlessly purchase the different products such as Auralief and Bloom at https://auraliefstrips.com and https://bloomarousal.com.
Joshua Maurice, COO, stated: “This proprietary online store will be deployed for LOVE’s over-the-counter therapeutics arm, for which the Company has 6 exclusive licenses, as previously announced. During the initial soft-launch phase, we are focused on direct-to-consumer sales, supported by integrated social media and digital marketing campaigns. The second phase of B2B sales will build on the success of our B2C marketing and awareness strategies. We are constantly assessing results to establish the most effective B2B launch using our proprietary e-commerce platform.”
Love Pharma recently announced a strategic investment in Starton Therapeutics. This investment was not to be interpreted as an official relationship or strategic alliance as it was primarily based upon the LOVE Pharma’s interest in innovative drug delivery technology, such as transdermal patches, which can reduce side effects, transforming patient outcomes with established, approved medicines allowing for streamlined market entry with long term IP protections.
Joshua Maurice, COO, added: “Love Pharma looks forward to building upon its strategic investment in Starton. While there is no promise or guarantee in regard to the outcome of the investment for Love Pharma investors, there is significant opportunity for the Company considering the robust catalog of IP and innovation Starton has diligently developed and continues to advance going forward.“
In order to grow its shareholder base, the company is in the process of applying for an OTC listing in the United States and has entered into new marketing and investor relations agreements. The company is well funded, having recently raised more than $2 million, with its shares currently trading at $0.02.
The information in this Investmentpitch Media Ltd video is for the viewers information only. Love Pharma has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format. The corporate information is based on information that is publicly available. Any information provided by Investmentpitch Media Ltd., through its media services is not to be construed as a recommendation or suggestion or offer to buy or sell securities but is provided solely as an informational media service. Investmentpitch Media Ltd makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the viewer or their financial advisor. Investing in securities is speculative and carries risk.
About InvestmentPitch Media
InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000’s of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.